498 related articles for article (PubMed ID: 24072562)
21. Drugs for rheumatoid arthritis.
Med Lett Drugs Ther; 2021 Nov; 63(1637):177-184. PubMed ID: 35085210
[No Abstract] [Full Text] [Related]
22. Drugs for rheumatoid arthritis.
Med Lett Drugs Ther; 2018 Jul; 60(1552):123-128. PubMed ID: 30044766
[No Abstract] [Full Text] [Related]
23. Pharmacotherapy Pearls in Rheumatology for the Care of Older Adult Patients: Focus on Oral Disease-Modifying Antirheumatic Drugs and the Newest Small Molecule Inhibitors.
Betancourt BY; Biehl A; Katz JD; Subedi A
Rheum Dis Clin North Am; 2018 Aug; 44(3):371-391. PubMed ID: 30001781
[TBL] [Abstract][Full Text] [Related]
24. Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice.
Huss V; Bower H; Wadström H; Frisell T; Askling J;
Rheumatology (Oxford); 2022 May; 61(5):1810-1818. PubMed ID: 34324640
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis.
Kerschbaumer A; Smolen JS; Ferreira RJO; Bertheussen H; Baraliakos X; Aletaha D; McGonagle DG; van der Heijde D; McInnes IB; Esbensen BA; Winthrop KL; Boehncke WH; Schoones JW; Gossec L
Ann Rheum Dis; 2024 May; 83(6):760-774. PubMed ID: 38503473
[TBL] [Abstract][Full Text] [Related]
26. Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs.
Pavelka K; Kavanaugh AF; Rubbert-Roth A; Ferraccioli G
Rheumatology (Oxford); 2012 Jul; 51 Suppl 5():v12-21. PubMed ID: 22718922
[TBL] [Abstract][Full Text] [Related]
27. Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK.
Aladul MI; Fitzpatrick RW; Chapman SR
BioDrugs; 2017 Dec; 31(6):533-544. PubMed ID: 29127626
[TBL] [Abstract][Full Text] [Related]
28. Four-year follow-up of atherogenicity in rheumatoid arthritis patients: from the nationwide Korean College of Rheumatology Biologics Registry.
Min HK; Kim HR; Lee SH; Shin K; Kim HA; Park SH; Kwok SK
Clin Rheumatol; 2021 Aug; 40(8):3105-3113. PubMed ID: 33576925
[TBL] [Abstract][Full Text] [Related]
29. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis.
Grijalva CG; Chung CP; Arbogast PG; Stein CM; Mitchel EF; Griffin MR
Med Care; 2007 Oct; 45(10 Supl 2):S66-76. PubMed ID: 17909386
[TBL] [Abstract][Full Text] [Related]
30. An overview of biologic disease-modifying antirheumatic drugs in axial spondyloarthritis and psoriatic arthritis.
So A; Inman RD
Best Pract Res Clin Rheumatol; 2018 Jun; 32(3):453-471. PubMed ID: 31171315
[TBL] [Abstract][Full Text] [Related]
31. Integrating Nanotechnological Advancements of Disease-Modifying Anti-Rheumatic Drugs into Rheumatoid Arthritis Management.
Singh S; Tiwary N; Sharma N; Behl T; Antil A; Anwer MK; Ramniwas S; Sachdeva M; Elossaily GM; Gulati M; Ohja S
Pharmaceuticals (Basel); 2024 Feb; 17(2):. PubMed ID: 38399463
[TBL] [Abstract][Full Text] [Related]
32. Monotherapy is a relevant option in rheumatoid arthritis treatment: a literature review.
Doria A; Zavaglia D
Clin Exp Rheumatol; 2019; 37(5):862-871. PubMed ID: 31376250
[TBL] [Abstract][Full Text] [Related]
33. Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis.
Schiff MH; Whelton A
Semin Arthritis Rheum; 2000 Dec; 30(3):196-208. PubMed ID: 11124283
[TBL] [Abstract][Full Text] [Related]
34. Mixed treatment comparison of the treatment discontinuations of biologic disease-modifying antirheumatic drugs in adults with rheumatoid arthritis.
Desai RJ; Hansen RA; Rao JK; Wilkins TM; Harden EA; Yuen A; Jonas DE; Roubey R; Jonas B; Gartlehner G; Lux L; Donahue KE
Ann Pharmacother; 2012 Nov; 46(11):1491-505. PubMed ID: 23092868
[TBL] [Abstract][Full Text] [Related]
35. [Adverse effects of biological therapy in rheumatology].
Olejárová M
Vnitr Lek; 2016; 62(7-8):605-12. PubMed ID: 27627085
[TBL] [Abstract][Full Text] [Related]
36. Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the Pharmaceutical Benefits Scheme?
Lu CY; Williams KM; Day RO
Intern Med J; 2007 Sep; 37(9):601-6. PubMed ID: 17542999
[TBL] [Abstract][Full Text] [Related]
37. Cardiovascular Risk of Synthetic, Non-Biologic Disease-Modifying Anti- Rheumatic Drugs (DMARDs).
Mourouzis IS; Manolis AS; Pantos C
Curr Vasc Pharmacol; 2020; 18(5):455-462. PubMed ID: 31566134
[TBL] [Abstract][Full Text] [Related]
38. Biosimilars in pediatric rheumatology and their introduction into routine care.
Aragon Cuevas O; Hedrich CM
Clin Immunol; 2020 Jul; 216():108447. PubMed ID: 32360950
[TBL] [Abstract][Full Text] [Related]
39. Remission in rheumatoid arthritis: wishful thinking or clinical reality?
Sesin CA; Bingham CO
Semin Arthritis Rheum; 2005 Dec; 35(3):185-96. PubMed ID: 16325659
[TBL] [Abstract][Full Text] [Related]
40. Disease-Modifying Antirheumatic Drugs (DMARDs) and drug interactions in dentistry.
Muñoz-Martínez C; Segura-Puertas M; Gómez-Moreno G
Eur Rev Med Pharmacol Sci; 2021 Apr; 25(7):2834-2842. PubMed ID: 33877648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
